Inivata to Present at Biotech Showcase alongside the JP Morgan Conference
Inivata is excited to be attending the JP Morgan Healthcare Conference and presenting at the 9th Annual Biotech Showcase conference: both taking place in San Francisco 9-11th January 2017. Inivata’s presentation at Biotech Showcase is on January 10th at 10:15am. Our CEO, Michael Stocum, CFO Tim Shannon, and VP of Corporate and Business Development, John Beeler will all be in attendance. To organize a meeting please contact us at firstname.lastname@example.org.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.